Blog

Paul Kluetz: I am pleased to announce that I am starting a new position as Chief Medical Officer at Paradigm Health

Paul Kluetz/paradigm.inc

May 3, 2025, 20:51

Paul Kluetz: I am pleased to announce that I am starting a new position as Chief Medical Officer at Paradigm Health

Paul Kluetz, Chief Medical Officer at Paradigm Health, shared on LinkedIn:

“I am pleased to announce that I am starting a new position as Chief Medical Officer at Paradigm Health. Paradigm Health is creating a research platform that leverages technology to enable access to trials for all patients while enhancing trial efficiency and reducing barriers to participate in research.

Paradigm Health is working with hundreds of clinical sites, many in rural locations in the U.S. where patients have had less access to clinical trials as a care option. I have been a strong advocate for improving patient access to trials and modernizing trial design and conduct, and this interest and passion aligns well with Paradigm Health’s mission.

I would like to thank and acknowledge the incredible colleagues I have had the honor of working alongside at the FDA. My time working through complicated applications and advancing efforts in clinical outcome assessments, clinical trial design, real-world data and other drug development topics has always been done as part of a larger team effort.

All along the way I’ve learned from so many talented multidisciplinary colleagues and have done my best to pay that forward by helping to mentor and develop early career scientific review staff who are the next rising stars.

I am excited for this next chapter and look forward to continuing to engage with the global research community as I work to help Paradigm Health achieve their goal to improve participation in clinical research for all patients.”

Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared Paul Kluetz’s post on LinkedIn:

“So thrilled that you have joined the team, Paul Kluetz. On behalf of the Paradigm Health Board, we could not be more enthusiastic about what we can accomplish, toward the critically important goal of increasing access to cancer clinical trials – the most advanced form of cancer care. I have every confidence that we are going to meaningfully move the dial on cancer, together!”

More posts featuring Karen Knudsen on OncoDaily.